BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17302569)

  • 1. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy.
    Okihara K; Ukimura O; Kanemitsu N; Mizutani Y; Kawauchi A; Miki T;
    Int J Urol; 2007 Feb; 14(2):128-32. PubMed ID: 17302569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 Nov; 17(11):950-5. PubMed ID: 20807265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
    BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
    Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
    Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
    Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
    J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical usefulness of chlormadinone acetate as an alternative antiandrogen therapy for prostate cancer relapse after combined androgen blockade therapy].
    Ehara H; Katoh S; Nakane K; Katoh T; Takada T; Kojima K; Kamei S; Hagiwara N; Yuhara K; Takahashi Y; Fujimoto Y; Fujihiro S; Kanimoto Y; Deguchi T
    Hinyokika Kiyo; 2009 Apr; 55(4):199-203. PubMed ID: 19462824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
    Miyake H; Hara I; Yamazaki H; Eto H
    Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
    Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
    Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H; Chodak GW; Hirao Y
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.